Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS

(2016) Yehuda Handelsman et al.   Endocrine Practice

Lessons from the bedside: ketoacidosis and SGLT2 inhibitors

(2016) Yvonne Y Chow et al.   MEDICAL JOURNAL OF AUSTRALIA

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes

(2015) Karen Whalen et al.   CLINICAL THERAPEUTICS

SGLT2 Inhibitors May Predispose to Ketoacidosis

(2015) Simeon I. Taylor et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperglycemic Crises in Adult Patients With Diabetes

(2009) A. E. Kitabchi et al.   DIABETES CARE